Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLHESP)

• Drug Name: Chlorothiazide Drug Info
• Synonyms: Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Chronic heart failure	BD1Z	Approved	[1]
Congestive heart failure	BD10	Approved	[2]
Edema	MG29	Approved	[1]

• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 2720
  ChEBI ID: CHEBI:3640
  CAS Number: CAS 58-94-6
  TTD Drug ID: DMLHESP
  VARIDT Drug ID: DR00646
  ACDINA Drug ID: D00122

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[10]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[11]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[12]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[13]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[13]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[14]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[15]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[16]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[19]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[20]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[21]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[22]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[23]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[24]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[26]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[29]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[30]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[31]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[32]
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[33]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[34]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[35]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[36]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[37]

Drug(s) Affected By Volume-regulated anion channel subunit LRRC8B (LRRC8B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[47]

Drug(s) Affected By Growth arrest-specific protein 7 (GAS7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[50]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[53]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[54]
Bortezomib	DMNO38U	Leukemia		Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[56]

Drug(s) Affected By LisH domain-containing protein ARMC9 (ARMC9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[60]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[61]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]

Drug(s) Affected By E3 ubiquitin-protein ligase NEDD4-like (NEDD4L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[65]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[68]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[69]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[70]

Drug(s) Affected By Protein-lysine 6-oxidase (LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[76]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[64]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]

Drug(s) Affected By Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (MGAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[78]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]

Drug(s) Affected By Adenylate cyclase type 9 (ADCY9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[57]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[81]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[82]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[81]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[84]

Drug(s) Affected By Beta-arrestin-1 (ARRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Bortezomib	DMNO38U	Leukemia		Approved	[55]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[87]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[89]

Drug(s) Affected By Endoplasmic reticulum-Golgi intermediate compartment protein 1 (ERGIC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[92]

Drug(s) Affected By Neutral ceramidase (ASAH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[93]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[94]

Drug(s) Affected By P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[96]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[97]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[98]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[99]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]

Drug(s) Affected By Protein phosphatase 1 regulatory subunit 12A (PPP1R12A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[102]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[103]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[104]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[105]

Drug(s) Affected By Protein argonaute-2 (AGO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[106]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[103]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[50]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]

Drug(s) Affected By Glutamate--cysteine ligase regulatory subunit (GCLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[108]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[110]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[111]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[112]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[113]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[116]

Drug(s) Affected By Zinc transporter ZIP11 (SLC39A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[117]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[118]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]

Drug(s) Affected By Triple functional domain protein (TRIO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[121]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Bortezomib	DMNO38U	Leukemia		Approved	[55]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]

Drug(s) Affected By Signaling threshold-regulating transmembrane adapter 1 (SIT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[101]

Drug(s) Affected By Cytosolic carboxypeptidase 4 (AGBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[124]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[125]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[126]

Drug(s) Affected By 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial (BCKDHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[112]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[127]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]

Drug(s) Affected By Apolipoprotein L3 (APOL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[77]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[128]

Drug(s) Affected By Proline-rich membrane anchor 1 (PRIMA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[117]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[117]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[126]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[129]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[130]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[131]

Drug(s) Affected By CD44 antigen (CD44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[132]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Selenium	DM25CGV	N. A.	N. A.	Approved	[135]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[136]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[137]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[121]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[138]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[139]

Drug(s) Affected By Golgi integral membrane protein 4 (GOLIM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[141]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[141]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[142]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[141]

Drug(s) Affected By Protein Jade-1 (JADE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[143]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[144]

Drug(s) Affected By Trinucleotide repeat-containing gene 6C protein (TNRC6C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[75]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[101]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[107]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[126]

Drug(s) Affected By NAD-capped RNA hydrolase NUDT12 (NUDT12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[130]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[145]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[146]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[39]

Drug(s) Affected By Carbonic anhydrase-related protein 10 (CA10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[147]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[148]

Drug(s) Affected By Actin-like protein 7B (ACTL7B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[149]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[150]

Drug(s) Affected By Growth/differentiation factor 3 (GDF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[151]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[53]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[87]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[87]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
paraquat	DMR8O3X	Discovery agent	N.A.	Investigative	[152]

Drug(s) Affected By Microtubule-associated tumor suppressor candidate 2 (MTUS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[153]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[130]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]
NAPQI	DM8F5LR	Autoimmune disease	4A40-4A45	Investigative	[155]

Drug(s) Affected By Coagulation factor V (F5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[117]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[117]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[156]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]

Drug(s) Affected By Storkhead-box protein 2 (STOX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[145]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[101]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[107]

Drug(s) Affected By Protein kinase C-binding protein NELL1 (NELL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[129]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[159]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[160]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[131]

Drug(s) Affected By Disabled homolog 2-interacting protein (DAB2IP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[161]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[129]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[145]

Drug(s) Affected By Unconventional myosin-X (MYO10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[162]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[163]
Promegestone	DMK4S8I	Gynecological disease	GA6Z	Approved	[164]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[134]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[165]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[166]
Fructose	DM43AN2	Vomiting	MD90	Approved	[167]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[168]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[169]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Ketotifen	DM74XKS	Allergic conjunctivitis	9A60.02	Approved	[170]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[171]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[171]

Drug(s) Affected By Sodium- and chloride-dependent transporter XTRP3 (SLC6A20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[108]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[172]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[173]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[149]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]

Drug(s) Affected By FYVE, RhoGEF and PH domain-containing protein 6 (FGD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[174]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[175]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[176]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[177]

Drug(s) Affected By Insulin-like growth factor I (IGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[178]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[179]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[180]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[181]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[182]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[183]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[184]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[185]

Drug(s) Affected By Cytochrome P450 7B1 (CYP7B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[186]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[188]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[189]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[188]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[128]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]

Drug(s) Affected By Pleckstrin homology-like domain family B member 1 (PHLDB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[173]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[99]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[191]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[101]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[101]

Drug(s) Affected By Muscarinic acetylcholine receptor M3 (CHRM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[192]
Carbachol	DMX9K8F	Glaucoma/ocular hypertension	9C61	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[117]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[195]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[196]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[196]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[197]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[197]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[197]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[198]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[199]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[200]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[201]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[202]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[203]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[204]

Drug(s) Affected By Natural killer cells antigen CD94 (KLRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[205]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[53]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]

Drug(s) Affected By Retinoic acid receptor RXR-alpha (RXRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[206]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Selenium	DM25CGV	N. A.	N. A.	Approved	[207]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[208]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[209]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[210]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[211]
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[212]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[141]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[213]

Drug(s) Affected By Kazrin (KAZN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[89]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[149]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[175]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[175]

Drug(s) Affected By Eyes absent homolog 2 (EYA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[215]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[47]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[77]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[191]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]

Drug(s) Affected By Piezo-type mechanosensitive ion channel component 2 (PIEZO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[47]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[191]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[107]

Drug(s) Affected By PR domain zinc finger protein 1 (PRDM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[162]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[216]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[141]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[141]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[141]
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[217]

Drug(s) Affected By Glutamate receptor ionotropic, NMDA 3A (GRIN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[130]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[218]
Interferon gamma-1b	DMWUMRL	Chronic granulomatous disease	4A00.0Y	Approved	[204]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[153]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[145]

Drug(s) Affected By Solute carrier family 35 member F1 (SLC35F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[219]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[128]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]
Mivebresib	DMCPF90	Acute myeloid leukaemia	2A60	Phase 1	[128]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]

Drug(s) Affected By Glutamate receptor ionotropic, NMDA 2A (GRIN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[221]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[222]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[126]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[39]
APR-246	DMNFADH	Ovarian cancer	2C73	Phase 2	[223]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]

Drug(s) Affected By Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (COX4I1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[224]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[225]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[226]
Mitotane	DMU1GX0	Adrenocortical carcinoma	2D11.Z	Approved	[227]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[228]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[204]

Drug(s) Affected By Oligodendrocyte transcription factor 3 (OLIG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[229]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[229]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[229]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[229]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[229]
Ramelteon	DM7IW9J	Insomnia	7A00-7A0Z	Approved	[229]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[230]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[229]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[219]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[229]

Drug(s) Affected By Protocadherin-15 (PCDH15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[149]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[149]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[101]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]

Drug(s) Affected By Erlin-1 (ERLIN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[55]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[78]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[231]

Drug(s) Affected By Matrilin-2 (MATN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[232]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[233]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[234]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[235]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]

Drug(s) Affected By PHD finger protein 10 (PHF10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[134]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[101]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[101]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[236]

Drug(s) Affected By Ras GTPase-activating-like protein IQGAP2 (IQGAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[237]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[59]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[153]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]

Drug(s) Affected By NIPA-like protein 2 (NIPAL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[238]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[130]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[176]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]

Drug(s) Affected By EF-hand calcium-binding domain-containing protein 11 (EFCAB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[239]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[177]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[145]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]

Drug(s) Affected By Juxtaposed with another zinc finger protein 1 (JAZF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[162]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[39]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[92]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[240]

Drug(s) Affected By Adhesion G-protein coupled receptor G6 (ADGRG6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[241]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[83]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[165]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[242]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[47]

Drug(s) Affected By Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[243]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[121]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[141]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[141]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[141]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]

Drug(s) Affected By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[244]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[245]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[246]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[247]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[246]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[205]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[248]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[249]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[250]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[246]

Drug(s) Affected By Myocyte-specific enhancer factor 2C (MEF2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[241]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[112]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[61]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[251]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[89]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[95]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[252]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[53]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[253]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[46]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[100]

Drug(s) Affected By F-box only protein 8 (FBXO8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[254]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[220]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[99]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[91]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[255]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[4]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
2-oxoisovalerate dehydrogenase subunit beta, mitochondrial (BCKDHB)	OT8OSVYU	ODBB_HUMAN	Drug Response	[6]
Actin-like protein 7B (ACTL7B)	OTCG3IGE	ACL7B_HUMAN	Drug Response	[7]
Adenylate cyclase type 9 (ADCY9)	OT1IZT5K	ADCY9_HUMAN	Drug Response	[8]
Adhesion G-protein coupled receptor G6 (ADGRG6)	OTY2UBXO	AGRG6_HUMAN	Drug Response	[6]
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (MGAT1)	OT1E09PZ	MGAT1_HUMAN	Drug Response	[6]
Apolipoprotein L3 (APOL3)	OT95SQHR	APOL3_HUMAN	Drug Response	[9]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Drug Response	[6]
Beta-arrestin-1 (ARRB1)	OT2NJS37	ARRB1_HUMAN	Drug Response	[6]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1)	OTYHXLWZ	BCAT1_HUMAN	Drug Response	[6]
Cancer/testis antigen 62 (CT62)	OTV9N4KM	CT62_HUMAN	Drug Response	[6]

References

• [1] Chlorothiazide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4835).
• [3] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [4] ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
• [5] Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73.
• [6] Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3. Epub 2013 Feb 12.
• [7] Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013 Sep;50(9):599-605. doi: 10.1136/jmedgenet-2012-101466. Epub 2013 Jun 17.
• [8] Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11.
• [9] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [10] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [11] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [12] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [13] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [14] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [15] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [16] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [17] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [18] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [19] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [20] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [21] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [22] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [23] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [24] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [25] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [26] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [27] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [28] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [29] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [30] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [31] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [32] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [33] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [34] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [35] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [36] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [37] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [38] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [39] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [40] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [41] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [42] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [43] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [44] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [45] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [46] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [47] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [48] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [49] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [50] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [51] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [52] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [53] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [54] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [55] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [56] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [57] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [58] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [59] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [60] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [61] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [62] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [63] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [64] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [65] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [66] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [67] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [68] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [69] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [70] Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem. 2004 Mar;88(5):1211-9. doi: 10.1046/j.1471-4159.2003.02247.x.
• [71] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [72] NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
• [73] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [74] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [75] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [76] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [77] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [78] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [79] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [80] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [81] Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole. Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):497-504. doi: 10.1007/s00210-018-01610-1. Epub 2019 Jan 3.
• [82] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [83] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [84] Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil. Cancer Invest. 2009 Jun;27(5):561-7.
• [85] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [86] Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. Acta Pharmacol Sin. 2006 Feb;27(2):165-72. doi: 10.1111/j.1745-7254.2006.00244.x.
• [87] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [88] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [89] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [90] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [91] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [92] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [93] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [94] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [95] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [96] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [97] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [98] Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2355-63.
• [99] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [100] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [101] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [102] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [103] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [104] Role of protein kinase D1 in vasoconstriction and haemodynamics in rats. Microvasc Res. 2024 Mar;152:104627. doi: 10.1016/j.mvr.2023.104627. Epub 2023 Nov 12.
• [105] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [106] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [107] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [108] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [109] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [110] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [111] Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochem Biophys Res Commun. 2009 Sep 11;387(1):109-14. doi: 10.1016/j.bbrc.2009.06.136. Epub 2009 Jul 1.
• [112] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [113] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [114] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [115] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [116] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [117] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [118] Cellular zinc homeostasis is a regulator in monocyte differentiation of HL-60 cells by 1 alpha,25-dihydroxyvitamin D3. J Leukoc Biol. 2010 May;87(5):833-44. doi: 10.1189/jlb.0409241. Epub 2010 Jan 20.
• [119] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [120] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [121] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [122] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [123] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [124] Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology. 2013 Sep;38(10):1864-70. doi: 10.1038/npp.2013.94. Epub 2013 Apr 12.
• [125] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [126] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [127] Characterisation of cisplatin-induced transcriptomics responses in primary mouse hepatocytes, HepG2 cells and mouse embryonic stem cells shows conservation of regulating transcription factor networks. Mutagenesis. 2014 Jan;29(1):17-26.
• [128] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [129] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [130] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [131] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [132] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [133] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [134] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [135] Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect. J Zhejiang Univ Sci B. 2008 Jan;9(1):22-33. doi: 10.1631/jzus.B071322.
• [136] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [137] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [138] Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
• [139] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [140] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [141] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [142] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [143] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [144] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [145] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [146] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [147] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [148] Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
• [149] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [150] Cultured human peripheral blood mononuclear cells alter their gene expression when challenged with endocrine-disrupting chemicals. Toxicology. 2013 Jan 7;303:17-24.
• [151] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [152] Paraquat affects the differentiation of neural stem cells and impairs the function of vascular endothelial cells: a study of molecular mechanism. Environ Toxicol. 2019 Apr;34(4):548-555. doi: 10.1002/tox.22723. Epub 2019 Jan 30.
• [153] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [154] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [155] Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci. 2011 Mar;120(1):33-41. doi: 10.1093/toxsci/kfq375. Epub 2010 Dec 22.
• [156] Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
• [157] Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation. Pediatr Hematol Oncol. 2000 Mar;17(2):177-80. doi: 10.1080/088800100276541.
• [158] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [159] Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007 Sep 20;26(43):6332-40. doi: 10.1038/sj.onc.1210461. Epub 2007 Apr 23.
• [160] Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012 Mar;13(4):399-405. doi: 10.2217/pgs.11.165.
• [161] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [162] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [163] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [164] Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7199-204.
• [165] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [166] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [167] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [168] Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
• [169] AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
• [170] Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
• [171] A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
• [172] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [173] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [174] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [175] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [176] BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52.
• [177] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [178] Insulin-like growth factors (IGF) I and II utilize different calcium signaling pathways in a primary human parathyroid cell culture model. World J Surg. 2006 Mar;30(3):333-45. doi: 10.1007/s00268-005-0339-8.
• [179] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [180] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [181] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [182] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [183] Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005 Aug 10;23(23):5334-46. doi: 10.1200/JCO.2005.03.723. Epub 2005 Jun 6.
• [184] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [185] DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
• [186] Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J Lipid Res. 1999 Dec;40(12):2195-203.
• [187] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [188] Regulation of steroid hydroxylase CYP7B1 by androgens and estrogens in prostate cancer LNCaP cells. Biochem Biophys Res Commun. 2006 Jun 2;344(2):540-6. doi: 10.1016/j.bbrc.2006.03.175. Epub 2006 Apr 4.
• [189] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [190] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [191] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [192] Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
• [193] Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. Toxicol In Vitro. 2010 Oct;24(7):1953-61. doi: 10.1016/j.tiv.2010.08.005. Epub 2010 Aug 12.
• [194] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [195] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [196] Assessment of false transmitters as treatments for nerve agent poisoning. Toxicol Lett. 2020 Mar 15;321:21-31. doi: 10.1016/j.toxlet.2019.12.010. Epub 2019 Dec 9.
• [197] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [198] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [199] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [200] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [201] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [202] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [203] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [204] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [205] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [206] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [207] Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. BMC Genomics. 2004 Aug 20;5(1):58. doi: 10.1186/1471-2164-5-58.
• [208] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [209] Identification and characterization of the human retinoid X receptor alpha gene promoter. Gene. 2006 May 10;372:118-27. doi: 10.1016/j.gene.2005.12.027. Epub 2006 Mar 6.
• [210] Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
• [211] Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
• [212] Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30.
• [213] The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem. 2004 Nov 5;279(45):47298-310. doi: 10.1074/jbc.M404101200. Epub 2004 Aug 25.
• [214] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [215] The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. PLoS One. 2012;7(4):e34806. doi: 10.1371/journal.pone.0034806. Epub 2012 Apr 24.
• [216] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [217] Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24;126(13):1565-74.
• [218] Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009 Jun;34(7):1819-28. doi: 10.1038/npp.2009.4. Epub 2009 Mar 18.
• [219] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [220] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [221] Early Transcriptomic Changes upon Thalidomide Exposure Influence the Later Neuronal Development in Human Embryonic Stem Cell-Derived Spheres. Int J Mol Sci. 2020 Aug 3;21(15):5564. doi: 10.3390/ijms21155564.
• [222] THC Treatment Alters Glutamate Receptor Gene Expression in Human Stem Cell-Derived Neurons. Mol Neuropsychiatry. 2017 Nov;3(2):73-84. doi: 10.1159/000477762. Epub 2017 Jul 20.
• [223] Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.
• [224] HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis. 2008 Aug;29(8):1528-37. doi: 10.1093/carcin/bgn125. Epub 2008 May 29.
• [225] Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor/ataxia syndrome: use of antioxidants in precision medicine. Mol Med. 2016 Oct;22:548-559. doi: 10.2119/molmed.2016.00122. Epub 2016 Jun 30.
• [226] Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem. 2010 Dec 17;285(51):39759-67. doi: 10.1074/jbc.M110.147504. Epub 2010 Sep 24.
• [227] Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81.
• [228] Erythropoietin activates SIRT1 to protect human cardiomyocytes against doxorubicin-induced mitochondrial dysfunction and toxicity. Toxicol Lett. 2017 Jun 5;275:28-38. doi: 10.1016/j.toxlet.2017.04.018. Epub 2017 Apr 27.
• [229] Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reprod Toxicol. 2020 Jan;91:74-91. doi: 10.1016/j.reprotox.2019.10.004. Epub 2019 Nov 8.
• [230] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [231] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [232] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [233] Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sci. 2016 Jun 15;155:29-35.
• [234] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [235] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [236] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [237] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [238] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [239] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [240] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [241] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [242] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [243] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [244] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [245] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [246] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [247] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [248] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [249] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [250] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [251] The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009 Feb;41(2):178-186.
• [252] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [253] Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
• [254] The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.
• [255] Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.